Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program
Identifiers
Identifiers
Date issued
2015Journal title
AMERICAN JOURNAL OF HEMATOLOGY
Type of content
Artigo